Paul van der Leest

8PUBLICATIONS
33CO-AUTHORS
Molecular targetsCancer diagnosisPredictive and prognostic markersLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 14, 2025
Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.

S L Aronson, B Thijssen, M Lopez-Yurda

|Sep 09, 2023
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.

Paul van der Leest, Melanie Janning, Naomi Rifaela

|Jan 07, 2022
Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

Sabrina Weber, Paul van der Leest, Hylke C Donker

|Aug 27, 2021
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.

Paul van der Leest, Birgitta Hiddinga, Anneke Miedema

|Oct 21, 2020
Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study.

Pierre-Jean Lamy, Paul van der Leest, Nicolas Lozano

|Jun 21, 2020
Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling.

Sabrina Weber, Benjamin Spiegl, Samantha O Perakis

Pageof 2

Frequent Collaborators

7 joint publications

Ed Schuuring

3 joint publications

Harry J M Groen

3 joint publications

Menno Tamminga

2 joint publications

Pierre-Jean Lamy